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Abstract
Background: Stem cell transplantation is a promising potential therapy for muscular dystrophies, but for this purpose, the
cells need to be systemically-deliverable, give rise to many muscle fibres and functionally reconstitute the satellite cell niche
in the majority of the patient’s skeletal muscles. Human skeletal muscle-derived pericytes have been shown to form muscle
fibres after intra-arterial transplantation in dystrophin-deficient host mice. Our aim was to replicate and extend these
promising findings.
Methodology/Principal Findings: Isolation and maintenance of human muscle derived cells (mdcs) was performed as
published for human pericytes. Mdscs were characterized by immunostaining, flow cytometry and RT-PCR; also, their ability
to differentiate into myotubes in vitro and into muscle fibres in vivo was assayed. Despite minor differences between human
mdcs and pericytes, mdscs contributed to muscle regeneration after intra-muscular injection in mdx nu/nu mice, the CD56+
sub-population being especially myogenic. However, in contrast to human pericytes delivered intra-arterially in mdx SCID
hosts, mdscs did not contribute to muscle regeneration after systemic delivery in mdx nu/nu hosts.
Conclusions/Significance: Our data complement and extend previous findings on human skeletal muscle-derived stem
cells, and clearly indicate that further work is necessary to prepare pure cell populations from skeletal muscle that maintain
their phenotype in culture and make a robust contribution to skeletal muscle regeneration after systemic delivery in
dystrophic mouse models. Small differences in protocols, animal models or outcome measurements may be the reason for
differences between our findings and previous data, but nonetheless underline the need for more detailed studies on
muscle-derived stem cells and independent replication of results before use of such cells in clinical trials.
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Introduction
Stem cell therapy is a potential promising approach for the
treatment of muscular dystrophies such as Duchenne muscular
dystrophy (DMD), in which muscle fibres degenerate due to lack of
the protein dystrophin [1–4]. Skeletal muscle regeneration is
mediated by muscle-specific stem cells called satellite cells [5]; their
progeny, myoblasts, can be expanded in culture and retain
myogenic differentiative capacity. Despite promising work in
mouse models of DMD [6], clinical trials of myoblasts in DMD
patients were disappointing [7–9], the main problems being low
survival and migration of grafted cells and the low number of
donor-derived muscle fibres [10]. Attention has therefore turned
to other types of stem cell, with the goal of finding a cell that can
be systemically-delivered, give rise to significant numbers of
muscle fibres in recipient muscles and functionally reconstitute the
muscle stem cell pool, so that dystrophin-negative muscle fibres
can be repaired later in life.
Amongst the many stem or precursor cells of human origin that
make at least some muscle in in vivo models of DMD [11–16],
blood-vessel associated stem cells - mesoangioblasts from embry-
onic stages or pericytes from adults - seem to be the most
promising [13,17–20]. Human muscle-derived pericytes gave rise
to large amounts of muscle after intra-arterial delivery in
immunodeficient, dystrophin-deficient (SCID mdx) mice [13].
However, despite expressing markers of pericytes and not
myoblasts, their precise origin is uncertain, as the method of
preparation could lead to contamination with other cell types, e.g.
satellite cells, endothelial cells, mesenchymal stem cells and
fibroblasts.
Here, we have isolated cells (termed muscle-derived cells, or
mdcs) from human muscle biopsies following the protocol used
previously to prepare human pericytes [13] and investigated their
phenotype and capacity to undergo myogenic differentiation in
vitro. Our cell preparations were phenotypically similar to pericytes
prepared by Dellavalle et al. in terms of expression of pericyte
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markers such as ALP and PDGFR-b, except that a proportion of
our cells in most of the preparations also expressed the myogenic
marker CD56. In addition, our cell preparations contained cells
expressing myogenic regulatory factors at the mRNA level prior to
their differentiation into myotubes, so we termed them mdcs
rather than pericytes. We also found differences in mdcs prepared
in the same way from 8 different donors - two preparations showed
extensive myogenic differentiation in vitro, four were less myogenic
and two entered senescence at early stages in culture. In vivo, in
contrast to human pericytes, which contribute to large numbers of
muscle fibres after intra-arterial transplantation, our mdcs,
especially the CD56+ subpopulation, contributed to muscle
regeneration only after intra-muscular transplantation in our
mdx nu/nu mouse model.
Materials and Methods
1. Ethics
Tissue sampling was approved by the NHS national research
ethics service Hammersmith and Queen Charlotte’s and Chelsea
Research Ethics Committee: Setting up of a rare diseases
biological samples bank (biobank) for research to facilitate
pharmacological, gene and cell therapy trials in neuromuscular
disorders (NMD) REC reference number: 06/Q0406/33, in
compliance with national guidelines regarding the use of biopsy
tissue for research. All patients gave written informed consent.
Mice were bred and experimental procedures were carried out
in the Biological Services Unit, Institute of Child Health,
University College London, in accordance with the Animals
(Scientific Procedures) Act 1986. Experiments were performed
under Home Office licence numbers 70/6228 or 70/7086.
Experiments were approved by the local University College
London ethical committee prior to the licence being granted.
2. In vitro isolation and maintenance of human muscle
derived cells
Human mdcs were isolated as previously described [13,21].
Muscle biopsies from 3 normal and 5 DMD patients (Table 1)
were cut into 1 mm3 pieces using a scalpel and placed as explants
into 35 cm2 culture dishes (Nunc) coated with collagen type I
(1 mg/ml from rat tail, Sigma). Explants were kept in M5 medium
(Megacell medium (Sigma) + 5% foetal bovine serum (FBS, PAA)
+ 2 mM glutamine (Sigma) + 1% non essential amino acids
(NEAA) + 0.1 mM b- mercaptoethanol (b-ME, Sigma) + 5 ng/ml
basic fibroblast growth factor (bFGF, Peprotech) for 10–14 days at
37uC in 5% O2 and 5% CO2. Small, refractory, non-adherent
cells were collected by gentle pipetting, transferred to new collagen
I-coated dishes and expanded in M10 medium (Megacell medium
(Sigma) + 10% FBS + 2 mMGlutamine + 1% NEAA + 0.1 mM b-
ME + 5 ng/ml bFGF), whilst adherent cells and the initial muscle
explants were discarded. Once cells reached confluence, the same
procedure was repeated to collect the small refractory cells and
expand them in new collagen 1-coated dishes. Cells generated
from the second dish were counted as passage 1, and mean
population doubling times (mpds) were determined from this
point. For long-term maintenance, cells were plated at a density of
2.56105 cells/75 cm2 flask, on the substrate and in the medium
described above. Cells were trypsinized and passaged every 3–4
days, and mpds were calculated by the following formula: mpd
increase = Ln [total cells/cells seeded]/Ln2 and doubling time
were calculated by time from seeding to harvesting/mpd. Total
mRNA from a small proportion of cells at each passage was
extracted for RT-PCR assay below. Aliquots of cells were frozen at
each passage and stored in liquid nitrogen for future studies.
3. in vitro analysis of mdcs
3.1 Semi-quantitative RT-PCR. Total RNA was extracted
from mdcs with RNAeasy mini preparation kit (Qiagen, West
Sussex, UK) following the manufacturer’s instructions. RNA was
quantified using Nanodrop 1000 3.6.0 (Thermal Scientific). For
each RT-PCR reaction, 10 ng of total RNA was used as template.
One-step RT-PCR was performed using primers designed to
recognize either the myogenic regulatory factors (MRFs) Pax3,
Pax7, Myf5, MyoD, desmin, myosin heavy chain (MHC) as
previously described [22], or other cellular markers: CD34,
PDGFR-b, NG2, ALP, GAPDH and CD144. The sequence of
the primers is listed in Table 2. PCR products were separated on
1% agarose gel for 20–30 min at 100 V and visualised with
SyberSafe DNA gel stain (Invitrogen) and GelDoc imaging
software (BioRad).
3.2 Flow cytometric analysis. Mdcs pN1, pD1 and pD2 at
mpds 15–30 were processed for flow cytometry. Cultured cells were
expanded for 3 days as described above before being detached from
the culture flasks using 0.05% trypsin20.2% EDTA (Sigma) and
centrifuged at 500 g for 5 min. The cell pellet was fixed with 4%
paraformaldehyde (PFA) for 15 min at room temperature for flow
cytometric analysis. 56105 cells were processed for each staining
and all procedures were performed at room temperature. Cells were
Table 1. Sources of human mdcs.
No. ID age sex Diagnosis Muscle of origin
Myogenicity (fusion
index) Comments
1. pN1 Adolescent idiopathic
scoliosis (AIS)
Para-spinal 4%
2. pN2 15 years F AIS Para-spinal 4.5%
3. pN3 14 years F AIS Para-spinal N/A Entered senescence at
early stages
4. pD1 4 years M DMD D42-43 Quadriceps 0.5%
5. pD2 11years M DMD D45-50 EDB 10–40%
6. pD3 11years M DMD D45-50 EDB 10–40%
7. pD4 4.5years M DMD (C.5503C-T, P.Gln1835X) Quadriceps Yes (intermediate level)
8. pD5 5 years M DMD with duplicated exon 3-9 Quadriceps N/A Entered senescence at
P6
doi:10.1371/journal.pone.0017454.t001
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blocked with PBS containing 1% bovine serum albumin (BSA) for
30 min before being incubated with primary antibodies for 1 hour,
followed by corresponding secondary antibodies for 30 min (Table
S1). Either secondary antibody alone, or PE/FITC conjugated
isotype matched antibodies, were used as controls. After staining,
cells were washed with PBS and analysed with a BD LSRII FACS
machine. 10,000 events were collected for each sample. Flowjo 7.2.5
software was used to analyse the results. FACS analysis was
performed at least 3 times for each marker on each cell preparation.
3.3 Immunofluorescent staining. Two cell preparations,
pN1 and pD2, at mpds 10–20 were used for immunofluorescent
analysis of marker expression. 16105 cells were plated onto 5 mg/
ml poly-D-lysine (PDL) coated coverslips and incubated overnight
before being processed for immunofluorescent staining. Staining
was performed at room temperature. Cells were fixed with 4%
PFA for 15 min and incubated with blocking solution (PBS
containing 10% normal goat serum (NGS)/0.3% Triton X100) for
30 min. Cells were then incubated with primary antibodies (listed
in Table S1) for 1 hour followed by Alexa 488-conjugated goat
anti- mouse or rabbit IgG (H+L) (Invitrogen, 1:500) for 1 hour.
Coverslips were then mounted with mounting medium (DAKO)
containing 10 mg/ml 49,6-diamidino-2-phenylindole (DAPI). Cells
stained with secondary antibody only were used as control.
3.4 In vitro myogenesis. To initiate myogenic differentiation,
mdcs were plated on 10 mg/ml laminin (Invitrogen) coated 8-well
chamberslides (Nunc) at 56104 cells/well in M2 medium (Megacell
medium containing 2% FBS). Medium was changed every 3–4 days
during differentiation. Cells were fixed at different time points after
plating and stained as described in material and methods section 3.3
with an antibody to myosin (MF20; DSHB), a marker of muscle
differentiation. Fusion index was determined by counting the
percentage of nuclei within MF20+ myotubes in 5 randomly-
encountered fields per well in 4 replicate wells. The cell preparation
(pD2) with the highest fusion index was chosen for all subsequent in
vitro and in vivo studies.
4. Separation of CD56 + and CD56- populations by flow
cytometry
pD2 mdcs at mpds 10.773, 16.165 and 25.772 were sorted into
CD56+ and – subpopulations. Cells were plated at 2.56105 cells/
75 cm2 flask for 3 days before being trypsinized and resuspended in
PBS containing 10% BSA and incubated with CD56:PE antibody
(Miltenyi biotech, 130-090-755,1:20) for 30 min at 4uC. Cells
incubated with mouse IgG1:PE (1:20) were taken as a negative
control. Cells were washed twice with PBS after antibody incubation,
and then sorted on the basis of CD56 expression using a MoFlo XDP
cell sorter. A small aliquot (approximately 16104 cells) of both CD56+
and CD56- cells was collected and processed for RT-PCR analysis (as
described in material and methods section 3.1). Sorted CD56+ and
CD56- subpopulations and non-sorted pD2 cells were expanded for
further in vitro analysis and intra-muscular transplantation.
To examine the myogenicity of CD56+ and – cells, pD2 cells
were sorted by flow cytometry on the basis of CD56 expression
and immediately plated onto laminin-coated chamberslides at
56104 cells/well in proliferation medium (M10). Differentiation
was induced 24 hours later by switching into differentiating
medium (M2). Cells were fixed at D1, D3, D5, and D7 after
differentiation and immunostained with antibodies to CD56,
myosin (MF20), Myf5, desmin, MyoD and myogenin. The
percentage of positive cells was counted as described above.
5. BrdU assay
CD56+ and CD56- subpopulations of pD2 cells were labelled
with bromodeoxyurindine (BrdU) and stained with an anti-BrdU
antibody (Table S1) to detect proliferating cells. Cells at mpds 20–
27 were plated onto 5 mg/ml Poly-D-Lysine coated 8-well
chamberslides at a density of 26104 cells/well for 24 hours in
M10 medium. 10 mM BrdU was then added to the culture
medium for 18 hours. Cells were then fixed with 4% PFA for
15 min, followed by treatment with 3N HCl for 10 min. Cells
were then stained with a BrdU antibody, as described in material
and methods section 3.3. The percentage of BrdU positive nuclei
was counted in 5 randomly-encountered fields at 106 using
Metamorph software; 3 wells were averaged each group, and the
experiment was repeated 3 times.
6. In vivo transplantation of mdcs
6.1 Intra-muscular transplantation of mdcs. 56105 cells
in 5 ml medium were grafted into cryodamaged tibialis anterior
(TA) muscles of 1–2 month old mdx nu/nu mice as previously
described [23,24]. First, we compared the capacity of pN1 (with a
low fusion index of 4%) and pD2 (fusion index 40%) to contribute
to muscle regeneration in vivo. For this experiment, cells injected
were at passage 5 (pN1, mpd 12.4) and passage 4 (pD2, mpd 9.8)
respectively and injected muscles were analyzed 28 days after
transplantation. Next, we grafted non-sorted and CD56+ and
CD562 subpopulations of pD2 and analyzed grafted muscles 4
and 8 weeks later.
In some experiments, grafted muscles were removed, frozen,
cryosectioned and stained with antibodies to human spectrin, human
lamin a/c and pan-laminin (Table S1) followed by Alexa 488
conjugated goat anti-mouse IgG (H+L) and Alexa 594 conjugated
goat anti-rabbit IgG (H+L) secondary antibody as described
previously [23,24]. Images of the transverse sections containing
most nuclei of human origin were captured with MetaMorph
software. The number of human lamin A/C+ nuclei, human
spectrin+ fibres, human spectrin+ fibres containing human lamin A/
C+ nuclei and the number of human lamin A/C+ nuclei inside or
Table 2. Primers used for identification of mdcs.
Forward primer Reverse primer Fragment size
CD34 AGAAAGGCTGGGCGAAGACCCT AGTGGGGAAGGGTTGGGCGT 311 bp
PDGFR-b CTGCGTCTGCAGCACGTGGA CTGCCCAAAGGCCCCAGAGC 357 bp
NG2 GTCCGACGGGCAACACCAGG CACTGGCCCTGCTTCCACGG 340 bp
ALP CTGACCACTGCCAGCCCACC GGGCAGCCGTCACTGTGGAG 294 bp
CD144 CCGCGGGAAACAGAGCCCAG ACTCGCCCTGCTCGTTGCAC 696 bp
GAPDH CCCATCACCATCTTCCAGGA TTGTCATACCAGGAAATGAGC 731 bp
doi:10.1371/journal.pone.0017454.t002
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outside basal lamina were counted using MetaMorph software and
compared using either Student’s t test or one-way ANOVA.
6.2 Intra-arterial transplantation of mdcs. Mdx nu/nu
mice at 1–2 months of age were anesthetised with isofluorane and
an incision was made in the groin to expose the femoral artery of
one hindlimb. The femoral artery was carefully dissected away
from the flanking femoral vein and nerve. A 30G insulin syringe
(Becton Dickinson) was inserted into the artery and 25 ml medium
containing 56105 cells was injected. Pressure was applied to
prevent blood loss from the artery. The skin was then sutured and
the mouse was given a subcutaneous injection of Vetergesic
(buprenorphine hydrochloride, 0.05 g/kg body weight). The con-
tralateral limb remained untreated. In preliminary experiments,
we injected 25 ml of 1% Evans blue instead of cells into the femoral
arteries of the right legs of host mice. The dye was immediately
seen along the downstream blood vessel network and the foot of
the injected leg became blue, demonstrating that our intra-arterial
injections were successful (data not shown). Details of intra-arterial
cell injections are given in Table 3. Two Mdc preparations, pN1
and pD2, were each injected intra-arterially into mdx nu/nu mice:
pN1 was injected into 13 host mice, 4 of which were analysed
2 hours after grafting and 9 of which were analysed 4 weeks after
grafting. pD2 was injected in to 9 host mice, all of which were
analysed 4 weeks after grafting. At each time point after trans-
plantation, TA muscles of the injected leg, the lung and liver were
processed for cryosectioning as described for intramuscular
transplantation.
Results
1. Mdcs exhibit long-term proliferative capacity before
entering senescence and express myoblast, pericyte and
mesenchymal stem cell markers
It has been reported that cells isolated and maintained with the
same protocol used in this study were pericytes, not satellite cells
[13]. Since our cell preparations have phenotypical differences
from cells described in this paper, we termed them mdcs.
Mdcs proliferated rapidly in vitro, but during the first few
passages, myotubes were observed within all cell preparations
(data not shown), suggesting that satellite cell-derived myoblasts
were present. The number of myotubes diminished after the first 2
passages and gradually the morphology of the cells became
homogenous and similar to that described for pericytes: a mixture
of small, triangular adherent cells and small, round floating cells
[13,21] (Figure 1a). The average mpd time of 4 separate mdc
preparations (pN1, pD1, pD2 and pD3) was 33.7961.24 hrs
(Figure 1b), similar to that of pericytes (36 hrs) [13], but shorter
than human synovial stem cells (54 hrs) [22] and human myoblasts
(49.7 hrs in low O2 and 60 hrs in high O2 conditions) (data not
shown). The proliferation curve of pN1 and pD2 cells shows that
our mdcs maintained their proliferative capacity until 30 mpds
before entering into senenscence (figure 1b), slightly longer than
reported for pericytes (20–25 mpds) [13].
Our mdcs expressed pericyte markers PDGFR-b (Figure 1g),
ALP (Figure 1g), CD49b (Figure 1d, 1g), CD146 (Figure S4a, a’)
and NG2 (detected by immunostaining, but not by flow cytometry)
(Figure 1c), which is in accordance with previous reports [13]. But,
although pericytes have been previously reported not to express
the myogenic marker CD56 [13], most cell preparations (pN1,
pD1, pD2, pD3, and pD5), maintained under our culture
conditions, contained a C56+ subpopulation, ranging from 1.49–
47% of the total population, as assessed by flow cytometric analysis
(Figure S1). Double labeling of CD56:PE and pericyte markers
showed that there were CD56+/ALP+, CD56+/CD146+ cells
within pD2, suggesting the pericyte origin of the CD56+ cell
subpopulation (Figure S4 c and d). In addition, mdcs contained
cells weakly expressing CD34, a marker expressed on satellite cells
[25,26], endothelial cells [27], hematopoietic stem cells [28,29],
myoendothelial cells [30], but not on pericytes [13]. To investigate
the presence of endothelial cells within our mdcs, we performed
FACS analysis of VE-Cadherin (CD144) and immunostaining of
Von Willenbrand Factor (vWF) on pD2 cells. pD2 cells did not
express VE-Cadherin (Figure S4 b and b’) or vWF (data not
shown). An angiogenesis assay on pD2 cells at 20 mpds (passage 9)
clearly showed that these cells made vessel-like structures
(Materials and Methods S1 and Figure S5).
In addition to pericyte and myogenic markers, the mesenchymal
stem cell markers CD29 (Figure 1e), CD44 (Figure1f), CD71
(Figure 1g), CD90 (Figure 1g) and Stro-1 (Figure 1g) [31,32], were
also expressed at similar levels by 3 mdc preparations (Figure 1).
Most of the above cell markers examined were expressed at similar
levels in the 3 cell preparations tested, except for PDGFR- b (ranging
from 29%–98%) and CD56 (ranging from 4 to 40%) (Figure S1).
2. Mdcs express myogenic factors at the RNA level but
show variable myogenesis
During proliferation in vitro, human pericytes do not express the
myogenic determination factors Pax7, Myf5, MyoD or MHC, but
they do express Pax3 at the RNA level [13]. However, RT-PCR
on the total mRNA extracted from the different passages (P2-P6,
equivalent to mpds 3–17) of 4 different mdc preparations (pN1,
pD1, pD2 and pD3) grown under proliferative conditions showed
that all four preparations expressed myogenic markers Pax3, Myf5
and MyoD. Two cell preparations, pN1 and pD1, also expressed
Pax7 at mpd3-7 (Figure 2a and data not shown). Expression of
Pax7, Myf5 and MyoD on pN1 and pD1 (2 cell preparations
exhibiting low myogenicity in vitro, Table 1) decreased with time in
culture (with the exception of MyoD expression, that did not
decrease significantly with time in pN1), whilst Pax3 expression
was maintained at the different mpds examined (Fig. 2a).
Expression of Myf5, MyoD and MHC were maintained in pD2
and pD3, two highly myogenic cell preparations (Table 1). These
Table 3. Summary of intra-arterial transplantation of mdcs.
Cell preparation Number of mice Time point
No. human lamin a/c cells in
downstream TA muscles
(Mean±SEM)
pN1 4 2 hrs 3.7560.48
pN1 9 4 weeks 1.1160.30
pD2 9 4weeks 8.6067.41
doi:10.1371/journal.pone.0017454.t003
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data suggest that in cell preparations with low myogenicity,
myogenic cells were present initially but were lost with increasing
time in culture; whilst in highly myogenic preparations, myogenic
cells persisted in vitro.
Mdcs pN1, pN2, pD1, pD2, pD3, pD4 at mpd 5–20 were
plated in differentiation conditions (material and methods section
3.4) and the fusion index calculated after 7 days. Cell preparations
from both normal and DMD muscles were myogenic to different
extents, ranging from 0–40% nuclei in myotubes (Table 1).
Although there were inter-experiment differences in fusion index,
pD2 mdscs retained their capacity to differentiate into myotubes
until at least 22.7 mpds (figure S3j).
The in vivo skeletal muscle regenerative capacity of different mdc
preparations correlated with their in vitro myogenic capacity. Two
mdc preparations with different in vitro fusion indices were grafted
intra-muscularly into cryodamaged TA muscles of mdx nu/nu
mice at passage 5 (pN1, mpd 12.4) and passage 4 (pD2, mpd 9.8)
respectively. Although similar numbers of donor nuclei were
present in muscles grafted with both preparations (Figure 2f), pN1,
with a fusion index of 4% at mpd7 (Figure 2b, Table 1) gave rise to
only 1.3360.33 (n= 6) fibres of donor origin (human spectrin+
fibres containing human lamin A/C+ nuclei) in vivo (Figure 2d,),
whereas pD2, with a 12–25% fusion index at mpd10.8 in vitro
(Figure 2c and Figure S3j), formed significantly more muscle fibres
of donor origin (Figure 2e) (P = 0.0020) in vivo (22.8365.19, n= 6)
than pN1 cells (Fig. 2f, g).
3. Human mdcs fail to contribute to skeletal muscle
regeneration after intra-arterial delivery
2 hours after intra-arterial injection of pN1, human lamin A/
C+ cells were detected in downstream TA muscles of the injected
leg (3.7560.48 per representative section), both inside (Figure 2i)
and outside the blood vessels (Fig. 2h). A few human lamin A/C+
cells were also detected in the lungs (figure 2j) of all mice examined
at 2 hours after grafting, but no human cells were detected in the
liver. 4 weeks after intra-arterial injection of pN1 and pD2, there
were only 1.1160.30 (pN1) and 8.6067.41 (pD2) human nuclei
per representative section of TA muscles of the grafted leg (Table 3,
Figure 2k); no muscle fibres of human origin were detected in any
TA muscles examined. At 4 weeks after grafting, no human cells
were detected in 7 lungs analysed.
We also performed experiments in which we did 2 intra-arterial
injections of the same cells into one femoral artery of 6 mdx nu/nu
mice at 28 days apart, sampling downstream TA and gastrocne-
mius muscles 42 days after the last injection. We found no muscle
of donor origin following these 2 injections.
4. CD56+ and CD56- subpopulations contribute
differently to myogenesis in vitro and skeletal muscle
regeneration in vivo
Our human mdc preparations contained between 0 and 40%
CD56+ cells (Fig. S1), which may have been either satellite cell-
derived myoblasts, or were generated during the culture period
from another cell type (e.g. pericytes). To determine whether
CD56+ and CD562 cells differed in their myogenic potential, we
separated these 2 cell populations from pD2 by flow cytometry and
analyzed their in vitro characteristics and myogenic properties and
in vivo contribution to myofibre regeneration.
4.1 pD2 cells that do not express CD56 give rise to CD56+
myogenic cells. Flow cytometric analysis of CD56 expression
was performed on pD2 at mpds 10.773, 16.165 and 22.273. The
percentage of CD56+ cells at each mpd was 6.20%, 32.86% and
Figure 1. Characterization and phenotype of human mdcs. a. Cultured human mdcs consisted of small, triangular adherent cells and small,
round floating cells. Scale bar = 50 mm. b. Proliferation curve of one normal human mdc preparation (pN1) and one DMD mdc preparation (pD1). The
average mean population doubling time for these cells is 33.7961.24 hrs. c, d, e, f. Representative images showing the expression of NG2 (c, green),
CD49b (d, green), CD29 (e, green) and CD44 (f, green) by pN1 human mdcs. Nuclei were counterstained with 10 mg/ml DAPI (blue). Scale bar
= 50 mm. g. Representative FACS images showing the expression of PDGFRb, ALP, CD49b, CD29, CD71, CD90, Stro-1, CD56 and CD34 by human mdcs.
Isotype control is shown in red in each image, and positive signal is shown in green. Note that most of these markers, apart from PDGFRb and CD56,
were expressed at similar levels among cell preparations (Figure S1).
doi:10.1371/journal.pone.0017454.g001
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8.69% respectively, showing that this molecule is not expressed at
consistent levels during cell culture.
The CD56+ and CD562 cells separated by FACS at D0
(Figure 3a) were then cultured as described in material and methods
section 2.2 and expression of CD56 was determined by flow
cytometry at 17 and 30 days after the initial separation. At 17 days
after separation, there were 85.72% CD56+ cells present in the
CD56+ subpopulation (Figure 3b), and 4.40% CD56+ cells present
in the CD562 subpopulation (Figure 3d). However, 30 days after
separation, there were only 17.62% CD56+ cells within the
subpopulation that was originally 100% CD56+ (Figure 3c), but in
contrast, 39.92% CD56+ cells were present in the originally CD562
subpopulation (Figure 3e). This shows that the CD562 fraction
(likely to contain human skeletal muscle pericytes) generates cells
capable of myogenesis, as shown by Dellavalle and colleagues [13].
4.2 CD56+ and CD562 display different myogenic
capacities both in vitro and in vivo. CD56+ and CD562
cells were left to differentiate (material and methods section 3.4) for
up to 21 days. Both CD56+ and CD562 cells differentiated into
myotubes in vitro, but with different kinetics (Figure 4). CD56+ cells
gave rise to myotubes from the second day after initiating
differentiation (data not shown). However, CD562 cells were
much slower in giving rise to myotubes. Expression of CD56,MF20,
Myf5, desmin, MyoD and myogenin by differentiating cells shows
that, although CD56+ cells initiated differentiation more rapidly,
CD562 cells differentiated to the same extent after a delay of 3–5
days (figure 4g). The decrease in fusion index in CD56+ cells may
due to loss of the already fully differentiated myotubes during the
long term in vitro maintenance, while the increase of the fusion index
in CD562 cells may due to the continuous maturation of the
myotubes during the culture period. The in vitro myogenic pattern of
CD562 cells was similar to that of human pericytes [13].
Next, CD56+, CD562 and non-sorted cells from pD2 was
transplanted intra-muscularly to investigate their contribution to
muscle regeneration. 4 weeks after grafting, CD56+ cells gave rise
to significantly more muscle cells or fibres of donor origin than
either CD562 (p,0.0001) or non-sorted cells (p,0.0001) (Figure 5
and Table 4). Interestingly, when we compared the percentage of
donor nuclei located inside the basal lamina (which must be either
myonuclei or satellite cells) between the three groups, the highest
percentage was found in the muscles grafted with CD56+ cells
(82.1565.94%, mean 6 SEM at 4 weeks and 86.8663.60%,
mean 6 SEM at 8 weeks after grafting). This indicates that a
higher percentage of cells within the CD56+ population were
myogenic, forming either myonuclei or satellite cells, than in the
CD562 or non-sorted populations (Figure 5). On grafting CD56+
Figure 2. Contribution of human mdcs to myogenesis in vitro and muscle regeneration in vivo. Expression of myogenic regulator factors
at the RNA level by 2 representative cell preparations, pN1 (low myogenic) and pD2 (highly myogenic) from passage 2 to passage 6, equivalent to
mpd 2 to 17. b, c. In vitro myogenesis of pN1(b) and pD2 (c) determined by myosin (MF20, green) immunostaining 7 days after in vitro differentiation,
nuclei were counterstained with 10 mg/ml DAPI (blue). Scale bar = 50 mm. d, e, f, g. Contribution of donor mdcs to nuclei and muscle fibres after
grafting pN1(d) and pD2 (e) into cryodamaged TA muscles of mdx nude mice. Transverse muscle sections were co-stained with human lamin A/C and
human spectrin (both red) to visualize the donor nuclei and donor muscles fibres. Total nuclei were counterstained with 10 mg/ml DAPI (blue). Arrows
point to 2 human spectrin+ fibres in figure d. Scale bar = 50 mm. f and g show the comparison of human lamin A/C+ cells and human spectrin+ fibres
between groups of muscles transplanted with different cell preparations. Data was analysed with Student’s t test. h, i, j, k. Mdcs did not contribute to
muscle regeneration after intra-arterial transplantation. Representative images show that, 2 hours after i.a. injection of mdcs, very few human lamin
A/C+ nuclei (green) were found either outside (h) blood vessels (vWF immunostaining, red) or (i) inside blood vessels; and few human lamin A/C+
nuclei (green) were present in the lungs of injected mice (j); 4 weeks after i.a. transplantation of mdcs, either no, or very few human lamin A/C +
nuclei (green, k) were detected in TA muscles of the injected mice. No human spectrin+muscle fibres were detected in any grafted mice. Nuclei were
counterstained with 10 mg/ml DAPI (blue). Scale bar = 100 mm for h, i and j, scale bar = 50 mm for k.
doi:10.1371/journal.pone.0017454.g002
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cells, there were significantly fewer cells (p = 0.002) and muscle
fibres of donor origin (p = 0.002 Student’s t test) at 8, compared to
4 weeks. However, in muscles grafted with either CD562 or non-
sorted cells, there were similar amounts of both donor muscle
fibres and donor nuclei at 4 and 8 weeks after grafting (Table 4).
4.3 Phenotypic differences of CD56+ and CD562 subsets
of pD2. To understand why CD56+ and CD562 cells behaved
so differently in terms of myogenesis and to determine if there is an
inter-relationship between CD562 and + cells, pD2 cells were
sorted on the basis of CD56 expression and analyzed to compare
their marker expression and proliferation properties.
RT-PCR analysis showed that neither CD56+ nor CD562 cells
expressed Pax7, but both expressed similar levels of Myf5 and
MyoD. However, the CD56+ cell population expressed more
desmin and MHC than the CD562 cell population, suggesting
that CD56+ cells were more differentiated than the CD562
population under proliferative conditions (Figure 6a).
Both CD56+ and CD562 cells expressed pericyte markers such
as ALP and NG2 at similar levels. In addition, both cell
populations expressed similar level of CD34 and CD144 at the
RNA level (Figure 6b).
Similar results were obtained by immunofluorescent staining for
the myogenic markers Pax7, Myf5, MyoD and desmin. Pax7
protein was not present on either CD56+ or CD562 cells and more
CD56+ cells expressed Myf5 (Figure S2) and desmin (Figure 6d) in
comparison with CD562 cells (Figure S2, 6e). MyoD was expressed
in the more confluent areas of CD56+ cell cultures, whereas fewer
CD562 cells expressed MyoD (Figure S2). There was similar level
of PDGFRb expression in CD562 and CD56+ cells (Figure 6f, g).
BrdU staining showed that 40.3462.193 of CD56+ cells and
52.4463.691 of CD562 cells (p = 0.048) were in S phase 3 days
after plating in proliferative medium, another indication that the
CD56+ sub-population might be undergoing slightly more
terminal differentiation than CD562 cells (Figure 6c, h, i).
In summary, the above data suggest that the CD56 expression
by pD2 cells was highly dynamic, with CD56+ cells being more
terminally differentiated myogenic cells than CD562 cells, as
indicated by their expression of desmin and MHC. However, the
expression of pericyte markers such as ALP, PDGFRb and other
endothelial markers such as CD34 and CD144 at the RNA level,
were similar in CD56+ and CD562 cells, suggesting that both
CD56+ and CD562 cells contained multiple cell types, including
pericytes, endothelial cells and possibly other cell types.
Discussion
A major goal of studies on the contribution of stem cells to
skeletal muscle regeneration is to identify the best human stem cell
for treatment of muscular dystrophies [11,13,30]. Such a stem cell
should be systemically-deliverable, contribute to widespread
muscle regeneration and ideally, functionally reconstitute the
muscle stem cell pool. Pericytes - stem cells associated with blood
vessels in postnatal tissues - have been derived from human skeletal
muscle and shown to contribute to muscle regeneration after
delivery via the femoral artery in the SCID mdx mouse, an
immunodeficient model of DMD [13]. We therefore wished to
replicate these promising findings, with the ultimate aim of
translating stem cell therapy to the treatment of DMD.
Figure 3. Dynamic expression of CD56 by pD2 cells during culture. FACS sorting of CD56+ (32.86%) and CD562 (34%) subpopulations from
pD2 at D0. b, c. Sorted CD56+ cells were maintained in culture for 17 days (b) and 30 days (c). FACS analysis of CD56 expression show that the
percentage of CD56+ cells in the initial CD56+ subpopulation was 85.72% (b) at 17 days and 17.42% (c) at 30 days. d, e. Sorted CD562 cells were
maintained in culture for 17 days (d) and 30 days (e). FACS analysis of CD56 expression show that the percentage of CD56+ cells in the initial CD562
subpopulation was 4.40% (d) at 17 days and 39.92% (e) at 30 days.
doi:10.1371/journal.pone.0017454.g003
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Stem cells within skeletal muscle
As skeletal muscle is capable of growth, repair and regeneration
that can be prevented by local high doses of radiation [33,34],
there must be stem or progenitor cells that mediate these processes
within the muscle itself. It is not clear how many stem cells (that
can give rise to a more differentiated cell type and self-renew) [35],
as opposed to progenitor cells that cannot self-renew, there are
within skeletal muscle. At least some satellite cells are muscle stem
cells, able to regenerate muscle fibres and reconstitute the satellite
cell niche with functional satellite cells [5]. Other stem/progenitor
cells within skeletal muscle include blood-vessel associated
mesoangioblasts [36] or pericytes [37], CD133+ cells [11], side
population cells [38,39], muscle derived stem cells [40–42],
endothelial cells [43], myoendothelial cells [30] and other
interstitial cells [44]. However, the relationship of these cell types
to each other and the extent to which they contribute to muscle
regeneration and/or reconstitute the satellite cell pool are unclear.
Difficulties in studying stem cells from skeletal muscle
A major problem with studying the different precursor or stem
cells within skeletal muscle, especially when possible clinical
applications are considered, is preparing pure populations of cells
for study. The different methodologies for isolation, culture and
analysis of muscle-derived cells by different laboratories have
Figure 4. CD56+ and CD562 mdscs have different kinetics of myogenesis in vitro. a, b, c, d, e, f. In vitro myogenesis of CD56+ (a, b, c) and
CD562 (d, e, f) cells after 7 days (a, d), 14 days (b, e) and 21 days (c, f) differentiation. Myosin (MF20, green) immunostaining was performed to
determine the fusion index at each time point. Total nuclei were counterstained with 10 mg/ml DAPI (blue). Scale bar = 50 mm. g. Quantification of
CD56+, Myosin (MF20)+, Myf5+, Desmin+, MyoD+ and myogenin+ cells within CD56+ and CD562 cell population during in vitro differentiation.
doi:10.1371/journal.pone.0017454.g004
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made it extremely difficult to make comparisons between the
studies. In addition, different muscles, or muscles from individuals
of different age [45,46], sex [47], or affected by different
pathological conditions, may contain different types or numbers
of stem cells, or they may function in a different way.
There is no standard method for releasing all cells from skeletal
muscles. In addition, alterations to connective tissue that occur as a
consequence of age or pathology make extraction of cells from
muscle even more challenging. The methods used, e.g. explant
culture, enzymatic disaggregation [21,23,24] and, for enzymatic
disaggregation, the type of enzyme used [13,30,48] and the timing
the of disaggregation may give rise to preparations containing
either different types or proportions of cell types and may also
remove cell surface markers [49]. Pre-plating was originally used
to remove the more adherent fibroblasts from a muscle cell
preparation [50], but has more recently been shown to enrich for a
particular type of muscle stem cell [41].
Sorting on the basis of cell surface antigens is frequently used to
define populations of stem cells [30,51], but does not give rise to
100% pure populations of cells and a minority cell within the
preparationmay give rise to misleading results. Sorting a specific stem
cell type from freshly-disaggregated postnatal human skeletal muscle
on the basis of cell surface marker expression has been reported for
AC133+ cells [11] and myoendothelial cells [30]; however, a
limitation of this approach is that too few cells are released from a
small biopsy for immediate sorting [30], therefore sorting is often
done following expansion of cells in vitro, which itself leads to changes
in muscle-derived cells [51]. The in vitro environment may either
affect a cell directly, by altering gene expression and phenotype [52–
54], or indirectly, by allowing one sub-population to predominate
over another. It is thought that the reason why culturing mouse
satellite cells has a profoundly detrimental effect on their subsequent
ability to regenerate skeletal muscle in vivo is because the cells begin to
differentiate in culture [55].
Figure 5. Contribution of CD56+, CD562 and non-sorted pD2 cells to muscle regeneration after intra-muscular transplantation into
cryodamaged TA muscles of mdx nu/nu mice. a–c. Representative images showing the contribution of CD56+ (a), CD562 (b) and non-sorted
pD2 cells (c) to muscle regeneration determined by human lamin A/C and human spectrin (both green) immunostaining. Total nuclei were
counterstained with 10 mg/ml DAPI (blue). Scale bar = 50 mm. d–f. Quantitative comparison of human lamin A/C+ nuclei (d), human spectrin+ fibres
(e) and spectrin+ fibres containing human lamin A/C+ nuclei (f) among 3 groups at 4 weeks and 8 weeks after transplantation. g. Quantitative
comparison of the percentage of human lamin A/C+ nuclei either inside or outside the basal lamina in each group at 4 weeks and 8 weeks after
transplantation. Numbers within the yellow bar show the number of human lamin A/C+ nuclei inside the basal lamina, numbers within the blue bar
show the number of human lamin A/C+ nuclei outside basal lamina, and numbers above each bar show the total number of human lamin A/C+
nuclei in each group.
doi:10.1371/journal.pone.0017454.g005
Table 4. Intra-muscular transplantation of CD56+, CD562 and non-sorted pD2 cells into cryodamaged TA muscles of mdx nu/nu
mice: contribution to human nuclei and human muscle fibres.
A. 4 weeks after grafting
Number/muscle section Donor cells
CD56+ CD56- Non-sorted P value among 3 groups
hLamin A/C+ nuclei (Mean6SEM)331.0610.32 (n = 4) 70.75613.70 (n = 8) 129.13620.78 (n = 8) p,0.0001
%hLamin A/C+ nuclei inside BL
(Mean6SEM)
82.265.9 (n = 4) 31.263.0 (n = 8) 31.264.9 (n = 8) p,0.0001
%hLamin A/C+ nuclei outside BL
(Mean6SEM)
17.865.9 (n = 4) 68.863.0 (n = 8) 68.864.9 (n = 8) p,0.0001
hSpectrin+fibres
(Mean6SEM)




213.25615.46 (n = 4) 32.6366.0 (n = 8) 34.8865.63 (n = 8) p,0.0001
B. 8 weeks after grafting
Number/muscle section Donor cells
CD56+ CD56- Non-sorted P value among 3 groups
hLamin A/C (Mean6SEM) 178.88624.54 (n = 8) 47.88615.08 (n = 8) 75.75618.40 (n = 8) p = 0.0003
%hLamin A/C inside BL
(Mean6SEM)
86.963.6 (n = 8) 70.267.7 (n = 7) 70.063.2 (n = 8) P = 0.0371
%hLamin A/C outside BL
(Mean6SEM)
13.163.6 (n = 8) 29.867.7 (n = 7) 30.063.2 (n = 8) P = 0.0371
hSpectrin+ fibres
(Mean6SEM)




110.25613.26 (n = 8) 24.2567.28 (n = 8) 37.00610.33 (n = 8) p,0.0001
doi:10.1371/journal.pone.0017454.t004
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Different muscles may contain either different numbers, or
types, of different muscle stem cell populations, but experiments
comparing the same stem cell derived from different human
muscles have not been done. In the experiments described here,
the same protocol was used by the same person to prepare cells
from eight different muscles (3 para-spinal, 3 quadriceps and 2
EDB muscles, Table 1). However, only two of these preparations,
pD2 and pD3, derived from the right and left EDB muscles of the
same DMD patient, were highly myogenic. One would need to
perform many more experiments to determine whether mdcs/
pericytes from one muscle are more myogenic than the same cells
from another muscle from the same individual, or whether age, sex
or pathological status has an effect on number, location or
activation status of resident stem or precursor cells.
As we did not use the same muscles as Dellavalle et al for our
cell preparations, direct comparison of our data with theirs is not
possible. However, our data complement and extend their
promising findings [13].
Our most myogenic mdc preparation, pD2, was derived from a
Duchenne muscular dystrophy patient aged 11 that had a deletion
of exons 45–50 in the dystophin gene, that could be put back in
frame by skipping exon 51 [56]. These cells also provide an
invaluable tool for studying the combination of exon skipping
strategies with stem cell therapy, which is ongoing in our
laboratory.
Comparison of muscle stem cells prepared by different
laboratories
Pericytes expressed annexin V, alkaline phosphatase (ALP),
desmin, smooth muscle actin, vimentin, PDGFRb, nestin, CD13
and CD44 but did not express M-cadherin, N-CAM (CD56),
cytokeratins, CD31, CD34, KDR, CD45, CD62L, CD71,
CD106, CD117, CD133. Cells were weakly-positive for CD49b,
CD63, CD90, CD105 and CD146. Clonal analysis showed that
20% of cells expressed smooth muscle actin or desmin, 50%
expressed NG2 and 90% expressed PDGF receptor b, and these
percentages did not change with successive passages in culture.
Only on terminal differentiation did they express MyoD and Myf5
[13].
Our human mdcs, prepared and cultured as described
previously [13], were similar phenotypically to pericytes, the main
difference being in the expression of myogenic markers – our cells
Figure 6. Phenotypic differences between CD56+ and CD562 cells. a. Expression of MRFs and other relevant markers at the RNA level in 2
batches of total RNAs extracted from 2 separate sorts of CD56+ and CD562 cells. b. Graph showing BrdU incorporation in CD56+ and CD56+ cells. c,
d. Expression of desmin (green) in CD56+ (d) and CD562 (e) cells. Nuclei were counterstained with 10 mg/ml DAPI (blue). Scale bar = 50 mm. e, f.
Expression of PDGFRb (green) in CD56+ (f) and CD562 (g) cells. Nuclei were counterstained with 10 mg/ml DAPI (blue). Scale bar = 50 mm. g, h.
Expression of BrdU (green) in CD56+ (h) and CD562 (i) cells. Nuclei were counterstained with 10 mg/ml DAPI (blue). Quantification of BrdU+ cells in
each population was compared with Student’s t test (b). Scale bar = 100 mm.
doi:10.1371/journal.pone.0017454.g006
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expressed Myf5, MyoD, MHC and Pax7 at the RNA level at early
stages under proliferative conditions, whereas pericytes did not.
This difference may be due either to the different sensitivities of
the RT-PCR methods used by the two laboratories, or to the fact
that our preparations, despite being prepared in the same way,
were a mixture of cell types, rather than being derived from
pericytes alone.
Another difference is that 5 out of 8 of our cell preparations
expressed CD56 (NCAM) [57]. CD56 is a regulator of cell
adhesion, intracellular signaling and cytoskeletal dynamics [58]
and is expressed by human satellite cells and myoblasts [59],
myoendothelial cells [30], NK cells [60], but not pericytes [13].
However, non-myogenic cells may express NCAM if they become
committed to the myogenic lineage: human synovial-derived
mesenchmal stem cells, which do not express CD56, did so after
being manipulated to overexpress MyoD and induced to undergo
myogenic differentiation (Materials and Methods S1 and Figure
S3a–h).
Both CD56+ and – subpopulations of pD2 expressed PDGFR-b,
ALP, NG2 and CD146, suggesting the presence of pericytes within
the preparation. We found that both the CD56+ and CD562 sub-
populations of pD2 mdcs underwent myogenesis in vitro, with CD56+
cells differentiating into myotubes more rapidly than CD562 cells.
Our data suggest, confirming the findings of Dellavalle et al, that
CD562 cells may represent a more primitive stem cell that can give
rise to more differentiated CD56+ cells during in vitro culture
(Figure 3). In support of this hypothesis, we found that CD562 cells
expressed fewer myogenic regulatory factors than CD56+ cells
(Figure 6a), implying that they are less committed to the myogenic
lineage than CD56+ cells. In addition, CD562 cells showed delayed
myogenesis in vitro compared to CD56+ cells, possibly because they
need to express CD56 before committing to myogenesis (Figure 4).
Finally, CD562 cells proliferated more rapidly than CD56+ cells
(Figure 6c, h and i), again indicating that they were less committed to
differentiation. However, future experiments using clonal analysis
would be necessary to determine whether CD562 cells do indeed
give rise to CD56+ progeny.
Contribution of different muscle-derived cells to muscle
regeneration
Pericytes, mesoangioblasts and AC133+ cells contribute to
muscle regeneration after intra-arterial delivery [11,13,19,20], but
our mdcs did not. This may be because either mdc preparations
did not contain pure pericytes, or that different host mouse strains
were used.
Both mdx nu/nu mice and mdx/SCID mouse strains have the
same mutation in their dystrophin gene, but are on different
genetic backgrounds and are immunocompromised in slightly
different ways: SCID mice have lower B cell function than nu/nu
mice, although both lack T cells and retain macrophage and NK
cell activity. Furthermore, SCID mice are ‘‘leaky’’ and may
generate mature lymphocytes as they age [61]. However, neither
nu/nu nor SCID mice are the optimal host for human cell
engraftment. To determine whether this had a significant effect on
donor cell engraftment, we grafted the same donor mdscs into
more highly immunodeficient C5-/Rag2-/gamma chain- host
mice [62], which are deficient in T, B and NK cells and have no
innate immunity [63], but are not dystrophic. We found similar
amounts of muscle of donor origin when cells were grafted into
cryodamaged TA muscles of mdx nu/nu and C5-/Rag2-/gamma
chain- host mice (Figure S3i), indicating that the choice of host
strain did not have a negative effect on engraftment efficiency.
Nevertheless, it remains possible that non-immunological factors
within different mouse strains have an impact on the regenerative
capacity of donor stem cells. Recent data have suggested that the
genetic background of mdx mice affects endogenous muscle
regeneration [64]. The genetic background of mdx SCID and
mdx nu/nu mice [6] will be different and this may contribute to the
differences between our findings and those of Dellavalle et al.
Different muscle injury models used for intra-muscular grafting
of putative muscle stem cells may also give rise to discrepancies
between groups. We grafted cells into muscles that had been cryo-
injured immediately prior to grafting [23,24,63], but Dellavalle et
al. grafted cells into muscles that had been injected 48 hours
previously with cardiotoxin, which induces muscle degeneration
and regeneration [13]. Pisani et al. used the same injury regime as
ours, but their hosts were immunodeficient Rag2-/gamma chain-
non-dystrophic mice [53] that lack NK cells and may therefore be
a better host for xenografts than SCID or nu/nu mice [63].
Vauchez et al. grafted into muscles of non-dystrophic SCID mice,
injuring the muscles prior to grafting by a combination of
irradiation and notexin [54]; Zheng et al. grafted cells into muscles
of SCID mice, that had been injured by cardiotoxin one day
previously [30]. How these different injury regimes model the
dystrophic muscle environment and to what extent the local
environment, genetic background and immunological status of the
host mouse affect muscle stem cell behavior are important to
determine, for the identification of robust methodologies which
could be reliably used for therapeutic trials in muscular dystrophies.
In addition to the injury model used, our intra-muscular
grafting experiments and methods of analysis differ slightly from
those of Dellavalle et al. All muscles were analysed a month after
grafting, but whereas Dellavalle et al used a human-specific
dystrophin antibody to identify fibres of human origin, we used
antibodies to human spectrin and lamin a/c. This was because a
human-specific dystrophin antibody would be non-informative for
identifying muscle fibres derived from stem cells prepared from
dystrophin-deficient DMD patients.
Interestingly, although they contributed to much muscle
regeneration after intra-arterial injection, pericytes only gave rise
to very small numbers of muscle fibres after intra-muscular
transplantation. CD56+/ALP- cells (satellite-cell derived myoblasts)
gave rise to more muscle than CD562/ALP+ cells (pericytes), but
CD562/ALP- cells, taken to be fibroblasts, made only the
occasional donor muscle fibre [13]. We also found that both
CD56+ and CD562 pD2 cells contributed to muscle regeneration,
CD56+ cells making significantly more muscle than either CD562,
or non-fractionated, cells after intra-muscular transplantation.
CD56+ cells contributed predominantly to nuclei inside the basal
lamina of muscle fibres, i.e. within either muscle fibres and/or
satellite cells. But CD562 or non-sorted cells contributed to
significantly more nuclei outside the basal lamina (Table 5),
confirming that there were more non-myogenic cells within
CD562 cell population.
Zheng et al showed that human skeletal muscle-derived CD56+
cells that also expressed CD34 and CD144 (characteristic of
myoendothelial cells) contributed to more muscle regeneration
than did CD56+/CD342/CD1442 cells (myoblasts) [30]. This
suggests that our CD56+ highly regenerative cell population may
contain myoendothelial cells, but our facs analysis (Figure S4)
showed that myoendothelial cells were rare. In addition, our
CD562 sub-population contained very few endothelial cells,
suggesting that pericytes, rather than endothelial cells, are the
major CD562 contributor to muscle regeneration.
Conclusions and future work
In conclusion, despite most of our findings being in agreement
with the findings of Dellavalle et al, we were not able to replicate
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the promising work showing that human pericytes gave rise to
considerable muscle regeneration following intra-arterial injection
in immunodeficient, dystrophin-deficient host mice [13]. It is not
entirely clear why this might be, but it is likely that our cell
preparations, despite being isolated according to the same
protocol, consisted of a mixture of myoblasts, myoendothelial
cells, endothelial cells and pericytes. In addition, there are some
minor technical differences between our experimental protocols
and those of Dellavalle et al. In both laboratories, cells were
initially plated on collagen; however, Dellavalle et al. then
expanded their cells on plastic, whereas we continued to use
collagen. Pericytes were re-suspended in PBS for grafting, whereas
mdscs were re-suspended in the medium in which they had been
grown. Lastly, for intra-muscular injection, we resuspended 56105
cells in 5 ml, whereas Dellavalle et al. resuspended the same
number of cells in 10 ml PBS [13]; for intra-arterial transplanta-
tion, we resuspended the cells in 25 ml medium, while Dellavalle et
al. resuspended the same number of cells in 60–70 ml PBS for
systemic injection [20]. Although these are minor variables, they
might account for the different results in the two laboratories.
Nevertheless, despite inter-preparation variability, our mdcs
were myogenic and contributed to muscle regeneration in vivo.
Furthermore, we showed that mdcs contained both CD56+ and –
cells, with cells expressing CD56+, a marker of both myoblasts and
myoendothelial cells, contributing to significantly more muscle
regeneration than CD562 cells.
However, to confirm that a particular stem cell does indeed
contribute to muscle regeneration after systemic or local delivery, the
cells would have to be prepared in a way that ensured that no
contaminating cell type was present, which is technically challenging.
In addition, the conditions under which the cells are expanded in vitro
must maintain stem cell characteristics. The resolutions of this
bottleneck will represent a significant step forward in the development
of this approach for the treatment of muscular dystrophies.
Supporting Information
Figure S1 Expression of PDGFRb (green) and CD56
(green) in 3 human mdc preparations (pN1, pD1 and
pD2) by flow cytometric analysis. Control was performed
using corresponding isotype control detailed in Table S1 (red).
Note the expression level of these cell markers were highly variable
among cell preparations.
(TIF)
Figure S2 Expression of Myf5 andMyoD (both green) by
CD56+ and CD56- sub-populations of pD2 cells. a, a’ and
a’’. Expression of Myf5 by CD56+ cells. b, b’ and b’’. Expression of
Myf5 by CD56- cells. c, c’ and c’’. Expression of MyoD by CD56+
cells. d, d’ and d’’. Expression of MyoD by CD56- cells. Nuclei were
counterstained with 10mg/ml DAPI (a, b, c and d). Scale bar=50mm.
(TIF)
Figure S3 a-h: Expression of CD56 on human synovial stem
cells that had been lentivirally-transduced to express hMyoD, 7
days after induction of differentiation in vitro. a-d) normal, non-
infected human synovial stem cells which were placed in
differentiation medium in parallel with e-h) hMyoD synovial stem
cells. Cells were stained for myosin (MF20, green) and CD56:PE
antibodies (red). Nuclei were counterstained with 10mg/ml DAPI
(blue). Scale bar = 50mm. i: Intramuscular transplantation of
CD56+, CD56- and non-sorted pD2 cells into cryodamaged TA
muscles of C5-/rag2-/c chain- mice. Quantification of the
number of human lamin a/c+ nuclei, human spectrin+ fibres
and human spectrin+ fibres containing human lamin a/c+ nuclei
showed that the contribution of each population of cells to C5-/
rag2-/c chain- mice were similar to that of transplantation into
mdx nu/nu mice (as shown in Figure 5). j: In vitro myogenesis of
pD2 cells at different mpds. Fusion index was determined by
counting the number of nuclei within MF20+ myotubes. Although
there were inter-experiment differences in fusion index, pD2
mdscs retained their capacity to differentiate into myotubes until at
least 22.7 mpds.
(TIF)
Figure S4 FACS analysis of expression of endothelial
markers and double staining of CD56:PE and ALP,
CD144, CD34 and CD146 on pD2 cells. a, a’: expression of
CD146 on pD2 cells. Approximately 76% of cells were CD146+
(a’). Mouse IgG1:FITC was used as isotype control (a) of
CD146:FITC antibody. b, b’: expression of CD144 on pD2 cells.
0.126% cells were CD144+ (b’). Rabbit IgG:FITC was used as
isotype control (b) of CD144:FITC antibody. c, d, e, f: Double
Table 5. Intra-muscular transplantation of CD56+, CD562 and non-sorted pD2 cells into cryodamaged TA muscles of mdx nu/nu
mice: percentage of donor nuclei inside or outside the basal lamina.
A: 4 weeks after grafting
Inside BL Outside BL
Mean SEM n Mean SEM n
CD56+ 82.15143 5.934744 4 17.84858 5.934745 4
CD562 57.65585 2.987688 8 42.34415 2.987688 8
Non-sorted 31.18838 4.894127 8 68.81161 4.894127 8
B: 8 weeks after grafting
Inside BL Outside BL
Mean SEM n Mean SEM n
CD56+ 86.85759 3.598443 8 13.14241 3.598443 8
CD562 70.23909 7.657588 7 29.7609 7.657588 8
Non-sorted 70.01827 3.152388 8 29.98173 3.152388 8
doi:10.1371/journal.pone.0017454.t005
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staining of pD2 cells with CD56:PE in combination with ALP (c),
CD146 (d), CD144 (e) and CD34 (f).
(TIF)
Figure S5 Angiogenesis of pD2 cells (mpd 20) in culture.
Tube formation can be observed 24 hours after being cultured in
10% FCS containing endothelial basal medium-2 on Matrigel
substrate (a). Cells cultured in serum-free medium (b) were taken
as negative control.
(TIF)
Table S1 Antibodies used for FACS analysis or immu-
nostaining.
(DOC)
Materials and Methods S1
(DOC)
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